Alexion Pharmaceuticals Inc. (ALXN1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ludwig N. Hantson
Employees:
2,656
100 COLLEGE STREET, NEW HAVEN, CT 06510
2032722596

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.

Data derived from most recent annual or quarterly report
Market Cap 40.336 Billion Shares Outstanding221.019 Million Avg 30-day Volume 8.344 Million
P/E Ratio49.9234 Dividend Yield0.0 EPS2.89
Price to Revenue5.436 Debt to Equity0.2133 EBITDA886.8 Million
Price to Book Value2.7413 Operating Margin9.151 Enterprise Value33.235 Billion
Current Ratio4.524 EPS Growth-0.709 Quick Ratio3.465
1 Yr BETA 0.7351 52-week High/Low 187.45 / 99.91 Profit Margin8.5441
Operating Cash Flow Growth40.2023 Altman Z-Score4.4853 Free Cash Flow to Firm 1.008 Billion
View SEC Filings from ALXN1 instead.

View recent insider trading info

Funds Holding ALXN1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALXN1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2021-07-22:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-20:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K/A: filed on 2021-05-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-11:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-04:
    Item 8.01: Other Events
  • 8-K: filed on 2021-04-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-03-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-02-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COUGHLIN CHRISTOPHER J

    • Director
    0 2021-07-21 0

    FRIEDMAN PAUL A

    • Director
    0 2021-07-21 0

    REINSDORF JUDITH A

    • Director
    0 2021-07-21 0

    DUNSIRE DEBORAH

    • Director
    0 2021-07-21 0

    NADER FRANCOIS

    • Director
    0 2021-07-21 0

    MOLLEN JOHN T

    • Director
    0 2021-07-21 0

    CHINIARA ELLEN EVP & CHIEF LEGAL OFFICER

    • Officer
    0 2021-07-21 0

    RUMMELT ANDREAS

    • Director
    0 2021-07-21 0

    HANTSON LUDWIG CEO

    • Officer
    • Director
    9,098 2021-07-21 0

    GOFF BRIAN EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    0 2021-07-21 0

    BRENNAN DAVID R

    • Director
    0 2021-07-21 0

    ORLOFF JOHN J EVP, RESEARCH & DEVELOPMENT

    • Officer
    0 2021-07-21 0

    FRANCHINI INDRANI LALL EVP, CHIEF COMPLIANCE OFFICER

    • Officer
    0 2021-07-21 0

    SARIN ARADHANA EVP, CFO

    • Officer
    0 2021-07-21 0

    BAZARKO DANIEL SVP, CONTROLLER, CAO

    • Officer
    0 2021-07-21 0

    CARINO TANISHA EVP & CCAO

    • Officer
    0 2021-07-21 0

    LAW ANNE-MARIE EVP, CHIEF EXPERIENCE OFFICER

    • Officer
    41,423 2020-06-08 0

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    BAKER FELIX

    BAKER JULIAN

    • Director
    9,071,539 2020-05-14 0

    CLANCY PAUL J EVP, CHIEF FINANCIAL OFFICER

    • Officer
    90,447 2019-07-11 0

    O'NEILL JULIE EVP. GLOBAL OPERATIONS

    • Officer
    51,727 2018-02-28 0

    WAGNER HEIDI L SVP, GLOBAL GOVERNMENT AFFAIRS

    • Officer
    49,140 2018-02-27 0

    MORIARTY JOHN B EVP & GENERAL COUNSEL

    • Officer
    74,537 2018-02-06 0

    VENEMAN ANN M

    • Director
    5,480 2017-09-05 0

    PARVEN ALVIN S

    • Director
    7,568 2017-06-15 0

    BURNS M MICHELE

    • Director
    4,353 2017-05-10 0

    NORBY R DOUGLAS

    • Director
    4,906 2017-05-10 0

    BELL LEONARD

    • Director
    390,670 2017-02-28 0

    THIEL CARSTEN EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    33,860 2017-02-28 0

    MACKAY MARTIN EVP & GLOBAL HEAD OF R&D

    • Officer
    50,688 2017-02-27 0

    CARMICHAEL CLARE EVP, CHIEF HR OFFICER

    • Officer
    39,161 2017-02-27 0

    MILLER EDWARD SVP, CHIEF COMPLIANCE OFFICER

    • Officer
    19,284 2017-02-27 0

    ANDERSON DAVID J EVP, CHIEF FINANCIAL OFFICER

    • Officer
    0 2016-12-12 0

    SINHA VIKAS EVP & CFO

    • Officer
    178,463 2016-08-08 0

    HALLAL DAVID CEO

    • Officer
    • Director
    189,266 2016-08-08 0

    ISLAM SAQIB EVP, CHIEF STRAT & PORT. OFF.

    • Officer
    43,799 2016-02-29 0

    MONNET DOMINIQUE SVP, CHIEF MARKETING OFFICER

    • Officer
    8,787 2015-05-20 0

    KELLER WILLIAM R

    • Director
    7,276 2014-12-04 0

    SQUINTO STEPHEN P EVP, CHIEF GLOBAL OPS. OFFICER

    • Officer
    106,508 2014-10-27 0

    LINK MAX

    • Director
    0 2014-05-05 0

    MADRI JOSEPH A

    • Director
    179,217 2014-03-11 0

    MATHIS LARRY

    • Director
    30,351 2014-02-28 0

    WRIGHT FRANK J SVP, PRESIDENT ALXN PHARM INTL

    • Officer
    19,670 2014-02-06 0

    COISSAC PATRICE SVP & PRES. ALXN PHARMA INT'L

    • Officer
    1,118 2012-10-31 0

    DUBIN THOMAS I H SVP & CHIEF LEGAL OFFICER

    • Officer
    65,705 2012-08-23 0

    WAEGER RUEDI E

    • Director
    24,054 2010-05-03 0

    KEISER DAVID W

    • Director
    149,546 2009-06-01 0

    MOJCIK CHRISTOPHER F SVP CLINICAL DEVELOPMENT

    • Officer
    257,581 2007-05-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 22:15:03 UTC -0.1724 0.2524 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 21:45:03 UTC -0.1724 0.2524 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 21:15:03 UTC -0.1724 0.2524 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 20:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 20:15:04 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 19:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 19:15:02 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 18:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 18:15:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 17:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 17:15:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 16:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 16:15:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 15:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 15:15:02 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 14:45:02 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 14:15:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 13:45:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 13:15:03 UTC -0.17 0.25 3900000
    ALEXION PHARMACEUTICALS INC ALXN 2021-07-21 12:45:03 UTC -0.17 0.25 3900000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments